Verrica Q1 Revenue Jumps 60% to $6.7M, Net Loss Narrows
Verrica Pharmaceuticals’ Q1 2026 revenue rose 60% year-over-year to $6.7 million, driven by higher ZILXI net product sales. Operating expenses declined 12% to $11.9 million, narrowing net loss to $5.2 million from $6.8 million a year earlier.
1. Revenue Growth and Sales Drivers
In Q1 2026, Verrica recorded $6.7 million in revenue, a 60% increase year-over-year, led by strong uptake of its lead product ZILXI. Expanded commercial reach and increased prescription volume contributed to the outsized growth in net product sales.
2. Expense Reduction and Loss Narrowing
Operating expenses fell 12% to $11.9 million as Verrica streamlined its SG&A and R&D spending. The cost reduction efforts helped narrow the net loss to $5.2 million, compared with a $6.8 million loss in Q1 2025.
3. Outlook and Management Commentary
Management reiterated its full-year revenue target of $30 million and plans to expand its sales force to support ZILXI penetration. The company also flagged upcoming clinical milestones for its pipeline assets, positioning it for potential upside in H2 2026.